可溶性VCAM-1/可溶性ICAM-1比值是诊断子宫内膜异位症的有前景生物标志物
本研究为前瞻性纵向研究,纳入138例因良性妇科疾病行腹腔镜的患者,其中97例分析;49例(50.5%)有子宫内膜异位症,48例(49.5%)无子宫内膜异位症为对照。结果显示异位内膜VCAM-1和ICAM-1 mRNA水平高于在位内膜(P<0.001),子宫内膜异位症患者正常腹膜mRNA水平也高于对照;血清sICAM-1较低(P=0.042)、sVCAM-1较高(P<0.001);sVCAM-1/sICAM-1比值AUC为0.929,阈值1.55时特异性86.7%、敏感性90.3%。
要点
- 子宫内膜异位症患者异位内膜VCAM-1和ICAM-1 mRNA水平高于在位内膜(P<0.001)。
- 子宫内膜异位症患者血清sVCAM-1高于对照(P<0.001)、sICAM-1低于对照(P=0.042)。
- sVCAM-1/sICAM-1比值诊断子宫内膜异位症AUC=0.929,阈值1.55时特异性86.7%、敏感性90.3%。
核心结论
- 子宫内膜和腹膜中VCAM-1与ICAM-1表达改变可能在子宫内膜异位症中起关键作用,可溶性VCAM-1/可溶性ICAM-1比值是有前景的生物标志物。
研究设计与样本
- 前瞻性纵向研究(Endometriosis Marker Austria),在大学附属三级子宫内膜异位症转诊中心对因良性妇科疾病行腹腔镜的患者进行研究。
- 2013年7月至2014年9月共纳入138例女性,其中97例在招募前至少3个月未接受激素治疗并纳入分析;49例(50.5%)有子宫内膜异位症,48例(49.5%)无子宫内膜异位症为对照组。
- 腹腔镜时取异位和在位内膜及正常盆腔腹膜组织,术前和术后6-10周采集血清;用定量实时PCR测VCAM-1、ICAM-1和EpCAM mRNA,用ELISA测血清可溶性VCAM-1(sVCAM-1)、可溶性ICAM-1(sICAM-1)和可溶性EpCAM(sEpCAM)蛋白水平。
主要发现
- 异位子宫内膜异位病灶中VCAM-1和ICAM-1 mRNA水平均高于在位内膜(P<0.001)。
- 子宫内膜异位症患者正常腹膜样本中VCAM-1和ICAM-1 mRNA水平高于对照(P=0.038和P=0.009)。
- 子宫内膜异位症患者在位内膜VCAM-1 mRNA水平高于对照(P=0.018)。
- 与对照相比,子宫内膜异位症患者血清sICAM-1较低(P=0.042)、sVCAM-1较高(P<0.001)。
- 血清sVCAM-1水平不受病灶类型、月经周期阶段或疾病严重程度影响;术前血清sVCAM-1预测子宫内膜异位症的AUC为0.868,阈值370 pg/ml时特异性80%、敏感性84%;sVCAM-1/sICAM-1比值AUC为0.929,阈值1.55时特异性86.7%、敏感性90.3%。
关键数值与推荐
- 术前血清sVCAM-1阈值370 pg/ml时,AUC 0.868,特异性80%,敏感性84%。
- sVCAM-1/sICAM-1比值阈值1.55时,AUC 0.929,特异性86.7%,敏感性90.3%。
临床怎么用
- 作者认为,通过检测血清sVCAM-1水平或sVCAM-1/sICAM-1比值诊断患者将具有相当大的临床价值。
- 作者认为,研究结果可能有助于开发新的无创诊断子宫内膜异位症的工具。
局限性
- 表达分析中样本量相对较小是本研究的可能局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
STUDY QUESTION: Do cell adhesion molecules play a role in endometriosis, and can they be used as a biomarker for diagnosing endometriosis? SUMMARY ANSWER: Altered expression of vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) in the endometrium and peritoneum may play a key role in endometriosis and the soluble VCAM-1/soluble ICAM-1 ratio is a promising biomarker. WHAT IS KNOWN ALREADY: Cell adhesion molecules are cell surface proteins that mediate cellular adherence, inflammatory and immune responses, and cancer-related biological processes. Altered expression of VCAM-1 and ICAM-1 in women with endometriosis has been investigated previously; however, gene expression levels in tissues and protein levels in the serum have not been investigated in the same patients. STUDY DESIGN SIZE, DURATION: We performed a prospective, longitudinal study (the Endometriosis Marker Austria) in patients who underwent a laparoscopy for benign gynecological pathology in a university-based tertiary referral center for endometriosis. From a total of 138 women who were included in the study from July 2013 through September 2014, 97 had not received hormonal treatment for at least 3 months prior to recruitment and were included in the analysis; 49 (50.5%) of these women had endometriosis, and the 48 (49.5%) who did not have endometriosis served as a control group. PARTICIPANTS/MATERIALS SETTING METHODS: During laparoscopy, tissue samples were obtained from ectopic and eutopic endometrium, and from normal pelvic peritoneum. In addition, serum samples were collected immediately before and 6-10 weeks after surgery. The mRNA levels of VCAM-1, ICAM-1 and epithelial cell adhesion molecule (EpCAM) were measured using quantitative real-time PCR, and serum protein levels of soluble VCAM-1 (sVCAM-1), ICAM-1 (sICAM-1) and EpCAM (sEpCAM) were measured using ELISA and correlated with endometriosis status. MAIN RESULTS AND THE ROLE OF CHANCE: The mRNA levels of both VCAM-1 and ICAM-1 were higher in ectopic endometriotic lesions than in eutopic endometrium (P < 0.001). Moreover, the mRNA levels of both VCAM-1 and ICAM-1 were higher in normal peritoneum samples obtained from women with endometriosis compared to those from controls (P = 0.038 and P = 0.009). The mRNA levels of VCAM-1 were also higher in the eutopic endometrium samples obtained from women with endometriosis compared to controls (P = 0.018). With respect to serum protein levels, compared to controls, the women with endometriosis had lower serum levels of sICAM-1 (P = 0.042) and higher levels of sVCAM-1 (P < 0.001). Our analysis revealed that the serum levels of sVCAM-1 were not affected by lesion entity, menstrual cycle phase or disease severity. An receiver operating characteristics curve, calculated to determine whether preoperative serum sVCAM-1 concentration can be used to predict endometriosis, found an AUC of 0.868 with 80% specificity and 84% sensitivity at a cutoff value of 370 pg/ml. This predictive performance can be further improved by calculation of the sVCAM-1/sICAM-1 ratio, leading to an AUC of 0.929 with 86.7% specificity and 90.3% sensitivity at a cutoff ratio value of 1.55. LARGE SCALE DATA: Not applicable. LIMITATIONS REASONS FOR CAUTION: The relatively small sample size in the expression analyses is a possible limitation of this study. WIDER IMPLICATIONS OF THE FINDINGS: Our findings could contribute to an improved understanding of the pathogenesis of endometriosis and the role of cell adhesion molecules. In addition, the results may lead to the development of new, non-invasive tools for diagnosing endometriosis. The ability to diagnose patients by measuring serum sVCAM-1 levels or the sVCAM-1/sICAM-1 ratio would have considerable clinical value. STUDY FUNDING/COMPETING INTEREST(S): The Ingrid Flick Foundation (Grant no. FA751C0801), which played no role in the study design, data collection and analysis, decision to publish or preparation of the manuscript. The authors declare no competing interests.
引用
- Kuessel L, Wenzl R, Proestling K, et al. Soluble VCAM-1/soluble ICAM-1 ratio is a promising biomarker for diagnosing endometriosis. Hum Reprod. 2017. PMID: 28333208. doi:10.1093/humrep/dex028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。